Exploring acetaminophen prodrugs and hybrids: a review.
Level 5 - mechanism / opinion, no new human data
Narrative review of chemical structures and drug design without primary human clinical trial data
PubMed 38525062 · doi:10.1039/d4ra00365a
What was done
The authors conducted a narrative review examining chemical strategies used to develop acetaminophen (APAP) derivatives, prodrugs, codrugs, and hybrids aimed at improving pharmaceutical properties and mitigating adverse effects. They established a structural classification system categorizing carrier-linked O-modified APAP, N-modified APAP derivatives, direct- and spacer-linked N,O-APAP hybrids (particularly ester and amide NSAID-APAP conjugates), C-linked hybrids, and nitric oxide-releasing APAP hybrids, evaluating examples such as propacetamol, benorylate, acetaminosalol, nitroparacetamol, and JNJ-10450232.
What was found
The abstract reports a conceptual structural classification framework for APAP-based conjugates and prodrugs. The abstract reports no quantitative results, statistical data, or numerical metrics of pharmacological efficacy or safety.
Why it matters
This framework clarifies the terminology and chemical relationships among APAP prodrugs and hybrids. It provides medicinal chemists with a systematic structure-activity relationship guide for designing novel analgesics with potentially improved safety profiles.
Limits
The review is qualitative and narrative rather than systematic. The abstract provides no quantitative pharmacological data, in vivo toxicity benchmarks, or clinical trial outcomes to evaluate whether these chemical modifications consistently improve clinical safety or efficacy over parent acetaminophen.
Cited by
- contradicts Acetaminophen belongs to the class of non-steroidal anti-inflammatory medications (NSAIDs).